source
- Lilly strikes second partnership this year for recombinase-based gene editingDecades before CRISPR gene editing was invented, scientists tried to manipulate genes with enzymes called recombinases. The proteins were precise but proved tricky to use because they were hardwire…Endpoints · 3mo ago↗ source
- Galapagos spinout Coultreon raises $125M for new take on SIK inhibitionCoultreon Biopharma has patched together $125 million from some of the largest biotech investors in the US and Europe in a bid to join the burgeoning pipeline-in-a-pill approach to autoimmune disea…Endpoints · 3mo ago↗ source
- Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.